MedTrace Logo

Azithromycin in the Treatment of M. Avium Complex Lung Disease

NCT00599079 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2017-05-23

No results posted yet for this study

Summary

To determine the safety and efficacy of azithromycin in the treatment of lung infection with M.avium complex and M. abscessus lung disease.

Conditions

  • Mycobacterium Avium Complex Lung Disease

Interventions

DRUG

Azithromycin

Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • The University of Texas Health Science Center at Tyler

    lead OTHER

Principal Investigators

  • Richard J Wallace Jr., M.D. · The University of Texas Health Science Center at Tyler

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-02-28
Primary Completion
2008-05-31
Completion
2017-05-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00599079 on ClinicalTrials.gov